POST Online Media Lite Edition



 

Quest Diagnostics completes acquisition of U.S. laboratory services business of Oxford Immunotec

Staff Writer |
Quest Diagnostics and Oxford Immunotec Global announced that Quest Diagnostics has completed its previously announced acquisition of the U.S. laboratory services business of Oxford Immunotec.

Article continues below




The T-SPOT.TB tuberculosis and the Accutix tick-borne disease testing services are now part of Quest Diagnostics' portfolio of innovative infectious disease testing services.

As part of the transaction, Oxford Immunotec will sell T-SPOT.TB test kits and related accessories to Quest Diagnostics under the terms of a long-term supply agreement. In addition, the parties have entered into a strategic collaboration agreement to drive continued growth of T-SPOT.TB testing in the U.S.

Quest Diagnostics intends to continue to offer QuantiFERON TB testing services to provide physicians choice in blood-based TB testing.


What to read next

Quest to buy Solstas for $570 million
Quest Diagnostics completes acquisition of Solstas
Quest Diagnostics acquires PhenoPath